Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Q32 Bio (QTTB) EPS (Weighted Average and Diluted) (2021 - 2026)

Q32 Bio's quarterly EPS (Weighted Average and Diluted) came in at -$0.54 in Q1 2026, up 40.0% year-on-year from -$0.39 in Q1 2025, and down 111.46% quarter-over-quarter from $4.71 in Q4 2025.

Q32 Bio has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$0.54 in Q1 2026.

  • For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 40.0% year-over-year to -$0.54; the trailing twelve-month figure through Mar 2026 stood at $2.79 (up 158.61% YoY), and the FY2025 full-year result was $2.42, up 136.78% from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.54, down from $4.71 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $4.71 in Q4 2025, with the low at -$77.15 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$9.57, with a median of -$0.9 recorded in 2025.
  • Year-over-year, EPS (Weighted Average and Diluted) surged 8050.0% in 2022 and sank 12758.33% in 2023.
  • Tracing QTTB's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.6 in 2022, then sank by 12758.33% to -$77.15 in 2023, then soared by 98.73% to -$0.98 in 2024, then surged by 580.61% to $4.71 in 2025, then slumped by 111.46% to -$0.54 in 2026.
  • The last three EPS (Weighted Average and Diluted) figures came in at -$0.54 (Q1 2026), $4.71 (Q4 2025), and -$0.6 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -4.43
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 4.02
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.51
10 Q32 Bio 162.94 Mn 112.19 Mn - -0.54

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.54
Dec 31, 2025 4.71
Sep 30, 2025 -0.60
Jun 30, 2025 -0.78
Mar 31, 2025 -0.90
Dec 31, 2024 -0.98
Sep 30, 2024 -1.46
Jun 30, 2024 -1.42
Mar 31, 2024 -6.33
Dec 31, 2023 -77.15
Sep 30, 2023 -40.52
Jun 30, 2023 -16.69
Mar 31, 2023 -19.84
Dec 31, 2022 -0.60
Sep 30, 2022 -0.59
Jun 30, 2022 -0.51
Mar 31, 2022 1.59
Dec 31, 2021 -0.59
Sep 30, 2021 -0.54
Jun 30, 2021 -0.54
Mar 31, 2021 -0.02